PDL BioPharma Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and PDL BioPharma are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PDL BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong essential indicators, PDL BioPharma is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Fifty Two Week Low | 2.0900 | |
| Target High Price | 2.50 | |
| Fifty Two Week High | 3.8600 | |
| Target Low Price | 2.50 |
PDL |
PDL BioPharma Relative Risk vs. Return Landscape
If you would invest (100.00) in PDL BioPharma on January 17, 2024 and sell it today you would earn a total of 100.00 from holding PDL BioPharma or generate -100.0% return on investment over 90 days. PDL BioPharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than PDL, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PDL BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PDL BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PDL BioPharma, and traders can use it to determine the average amount a PDL BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PDLI |
Based on monthly moving average PDL BioPharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PDL BioPharma by adding PDL BioPharma to a well-diversified portfolio.
PDL BioPharma Fundamentals Growth
PDL Stock prices reflect investors' perceptions of the future prospects and financial health of PDL BioPharma, and PDL BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PDL Stock performance.
| Return On Equity | -7.36 | |||
| Return On Asset | -4.1 | |||
| Operating Margin | (166.77) % | |||
| Current Valuation | 213.07 M | |||
| Shares Outstanding | 114.23 M | |||
| Price To Earning | 526.67 X | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 11.03 X | |||
| Revenue | 27.76 M | |||
| EBITDA | (42.98 M) | |||
| Cash And Equivalents | 105.45 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 13.51 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 3.69 X | |||
| Cash Flow From Operations | (56.35 M) | |||
| Earnings Per Share | (1.32) X | |||
| Total Asset | 1.01 B | |||
| Retained Earnings | 594.7 M | |||
| Current Asset | 282.71 M | |||
| Current Liabilities | 36.74 M | |||
Things to note about PDL BioPharma performance evaluation
Checking the ongoing alerts about PDL BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PDL BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PDL BioPharma is not yet fully synchronised with the market data | |
| PDL BioPharma has some characteristics of a very speculative penny stock | |
| PDL BioPharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 27.76 M. Net Loss for the year was (39.18 M) with profit before overhead, payroll, taxes, and interest of 13.43 M. | |
| PDL BioPharma currently holds about 105.45 M in cash with (56.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Over 97.0% of the company shares are owned by institutional investors |
- Analyzing PDL BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PDL BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining PDL BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PDL BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PDL BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PDL BioPharma's stock. These opinions can provide insight into PDL BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in PDL Stock
If you are still planning to invest in PDL BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PDL BioPharma's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |